4/2
01:59 pm
anro
Alto Neuroscience (ANRO) had its price target lowered by Robert W. Baird from $41.00 to $38.00. They now have an "outperform" rating on the stock.
Medium
Report
Alto Neuroscience (ANRO) had its price target lowered by Robert W. Baird from $41.00 to $38.00. They now have an "outperform" rating on the stock.
4/2
12:38 pm
anro
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
4/2
10:57 am
anro
Alto Neuroscience (ANRO) had its price target lowered by JonesTrading from $49.00 to $44.00. They now have a "buy" rating on the stock.
Low
Report
Alto Neuroscience (ANRO) had its price target lowered by JonesTrading from $49.00 to $44.00. They now have a "buy" rating on the stock.
4/2
09:41 am
anro
Alto Neuroscience (ANRO) had its price target lowered by Wedbush from $22.00 to $21.00. They now have a "neutral" rating on the stock.
Medium
Report
Alto Neuroscience (ANRO) had its price target lowered by Wedbush from $22.00 to $21.00. They now have a "neutral" rating on the stock.
4/2
08:12 am
anro
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $30.00 price target on the stock.
Medium
Report
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $30.00 price target on the stock.
4/1
04:40 pm
anro
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements [Yahoo! Finance]
Low
Report
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements [Yahoo! Finance]
4/1
04:30 pm
anro
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
Medium
Report
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
3/21
01:31 am
anro
Medium
Report
3/16/2026
06:03 am
anro
alto neuroscience, inc.
MISS
Report
8.6%
alto neuroscience, inc.
11/12/2025
07:57 am
anro
alto neuroscience, inc.
BEAT
Report
2.6%
alto neuroscience, inc.
8/13/2025
04:10 pm
anro
alto neuroscience, inc.
MISS
Report
-0.3%
alto neuroscience, inc.
5/14/2025
04:10 pm
anro
alto neuroscience, inc.
BEAT
Report
10.5%
alto neuroscience, inc.
4/10
04:01 pm
anro
Form S-3 Alto Neuroscience, Inc.
High
Report
Form S-3 Alto Neuroscience, Inc.
4/1
04:55 pm
anro
Form 8-K Alto Neuroscience, Inc. For: Apr 01
Medium
Report
Form 8-K Alto Neuroscience, Inc. For: Apr 01
3/26
04:11 pm
anro
Form ARS Alto Neuroscience, Inc. For: Dec 31
Low
Report
Form ARS Alto Neuroscience, Inc. For: Dec 31
3/26
04:08 pm
anro
Form DEFA14A Alto Neuroscience, Inc.
Low
Report
Form DEFA14A Alto Neuroscience, Inc.
3/26
04:06 pm
anro
Form DEF 14A Alto Neuroscience, Inc. For: May 12
Low
Report
Form DEF 14A Alto Neuroscience, Inc. For: May 12
3/16
07:08 am
anro
Form 8-K Alto Neuroscience, Inc. For: Mar 16
Low
Report
Form 8-K Alto Neuroscience, Inc. For: Mar 16
3/16
06:45 am
anro
Form S-8 Alto Neuroscience, Inc.
Medium
Report
Form S-8 Alto Neuroscience, Inc.
3/16
06:08 am
anro
Form 10-K Alto Neuroscience, Inc. For: Dec 31
Medium
Report
Form 10-K Alto Neuroscience, Inc. For: Dec 31
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register